OncoMatch/Clinical Trials/NCT05716516
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Is NCT05716516 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Estradiol for metastatic breast cancer.
Treatment: Estradiol — Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Demographics
Prior therapy
Must have received: endocrine therapy (tamoxifen, aromatase inhibitor, fulvestrant) — advanced/metastatic
Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting
Cannot have received: investigational cancer therapy
Any investigational cancer therapy in the last 3 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05716516 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational cancer therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages